Feb. 06, 2019

Teijin Limited
JCR Pharmaceuticals Co., Ltd.

Teijin Limited (Teijin) and JCR Pharmaceuticals Co., Ltd. (JCR) announced today that JTR-161, an allogeneic regenerative medical product composed of dental pulp stem cells (DPCs), have been administered to the first patient in Japan-based Phase I/II clinical trials, for the indication of acute cerebral infarction (stroke). Teijin and JCR signed a co-development and license agreement for JTR-161 in Japan in July 2017.

The trial is examining the safety and effectiveness of intravenously administered JTR-161 for patients who have suffered acute cerebral infarction. Teijin Pharma Limited, the core company of the Teijin group’s healthcare business, will conduct clinical studies and JCR will manufacture the investigational JTR-161 product for the clinical trials.

Teijin and JCR expect that JTR-161 contributes to the quality of life of patients as a new treatment option for acute cerebral infarction. It is composed of DPCs isolated from human teeth, of which extraction is less invasive than bone marrow extraction and are available in Japan. DPCs are also considered to pose a minimal risk of immunological rejection. JTR-161 is expected to demonstrate its effective suppression of inflammation by immune regulatory factors as well as promotion of regenerating organs by trophic factors.

Going forward, Teijin and JCR will continue collaborating in joint research and development, aiming to launch a commercial product as quickly as possible.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 170 companies and around 19,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY835 billion (USD 7.6 billion) and total assets of JPY 986.2 billion (USD 9 billion) in the fiscal year ending March 31, 2018.
Please visit www.teijin.com

About JCR Pharmaceuticals

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy,“Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

Back to 2019 News Release

Page Top